Extract
In patients with fibrotic interstitial lung disease (ILD), hypoxaemia on exertion is frequent, and contributes to exercise intolerance, exertional dyspnoea and reduced quality of life [1–3]. Clinically significant exertional hypoxaemia is typically defined as a drop in transcutaneous arterial oxygen saturation (SpO2) to ≤88% on a 6-min walk test (6MWT) [4], and is associated with reduced survival in ILD patients [5].
Abstract
In patients with interstitial lung disease, exertional hypoxaemia has quality of life and prognostic implications. A simple “DeOX” score predictive of exertional oxygen desaturation (SpO2 ≤88% on 6MWT) is proposed, using SpO2 at rest and DLCO. http://bit.ly/36ytigE
Footnotes
Conflict of interest: V. Alfieri has nothing to disclose.
Conflict of interest: E. Crisafulli has nothing to disclose.
Conflict of interest: D. Visca has nothing to disclose.
Conflict of interest: W.H. Chong has nothing to disclose.
Conflict of interest: C. Stock has nothing to disclose.
Conflict of interest: L. Mori has nothing to disclose.
Conflict of interest: A. de Lauretis has nothing to disclose.
Conflict of interest: V. Tsipouri has nothing to disclose.
Conflict of interest: F. Chua reports lecture fees and advisory board fees from Boehringer Ingelheim and from Roche, outside the submitted work.
Conflict of interest: V. Kouranos has nothing to disclose.
Conflict of interest: M. Kokosi has nothing to disclose.
Conflict of interest: C. Hogben has nothing to disclose.
Conflict of interest: P.L. Molyneaux has, via his institution, received industry-academic funding from Roche, Boehringer Ingelheim and Galapagos and has received speaker fees from Roche.
Conflict of interest: P.M. George reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche, personal fees from Teva, outside the submitted work.
Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speaker fees from Apellis, AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R&D, Indalo, Novartis, Pliant, ProMetic, Respivnat, Roche, Samumed and UCB.
Conflict of interest: A.A. Chetta has nothing to disclose.
Conflict of interest: P. Sestini has nothing to disclose.
Conflict of interest: A.U. Wells reports lecture fees and advisory board fees from Boeringher Ingelheim, Roche and Bayer, outside the submitted work.
Conflict of interest: E.A. Renzoni reports lecture fees and advisory board fees from Boeringher Ingelheim and Roche, and lecture fees from Mundipharma, outside the submitted work.
- Received August 28, 2019.
- Accepted October 25, 2019.
- Copyright ©ERS 2020
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
